<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04190602</url>
  </required_header>
  <id_info>
    <org_study_id>PR-610414-101</org_study_id>
    <nct_id>NCT04190602</nct_id>
  </id_info>
  <brief_title>Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System</brief_title>
  <acronym>AcChord</acronym>
  <official_title>The AcChord Study: A Multicenter Post-Market Observational Registry of the NeoChord Artificial Chordae Delivery System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoChord</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoChord</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the 5-year outcomes of participants with
      degenerative mitral valve disease treated with the NeoChord Artificial Chordae System, Model
      DS1000 in a post-market setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an observational, single-arm, multicenter post-market registry. Both
      prospective and retrospective enrollment will be allowed. No additional invasive or
      burdensome examinations outside those routinely required for the standard mitral valve repair
      procedure will be requested.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2020</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Level of Mitral Regurgitation Following the Index Procedure</measure>
    <time_frame>Completion of Index Procedure</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 3-6 Months</measure>
    <time_frame>3-6 Months</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 3 Years</measure>
    <time_frame>3 Years</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 4 Years</measure>
    <time_frame>4 Years</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of Mitral Regurgitation at 5 Years</measure>
    <time_frame>5 Years</time_frame>
    <description>Level of mitral regurgitation per echocardiography</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Freedom from Mitral Valve Re-intervention</measure>
    <time_frame>From enrollment until date of mitral valve reintervention, up to 5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from All-Cause Mortality</measure>
    <time_frame>From enrollment until date of death, up to 5 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Mitral Regurgitation</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Mitral Valve Insufficiency</condition>
  <condition>Mitral Valve Prolapse</condition>
  <condition>Heart Valve Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NeoChord Artificial Chordae Delivery System, Model DS1000</intervention_name>
    <description>The intended use of the device is for the placement of artificial chordae when the natural chordae tendinae have become elongated or ruptured due to degenerative valve disease.</description>
    <other_name>NeoChord DS1000</other_name>
    <other_name>DS1000</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients who meet the indications and are not contraindicated for treatment by the
        NeoChord Artificial Chordae Delivery System, Model DS1000.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has Grade III Moderate or Grade IV Severe degenerative or mixed disease mitral valve
             regurgitation

          -  Study procedure completed after 31 December 2016

        Exclusion Criteria:

          -  Heavily calcified valves

          -  Valvular retraction with severely reduced mobility

          -  Active bacterial endocarditis

          -  Complex mechanism of MR (leaflet perforation, etc.)

          -  Significant tethering of leaflets

          -  Inflammatory valve disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Beiras Fernandez, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johannes Gutenberg University Mainz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexandar Jonkers</last_name>
    <phone>+31 610740977</phone>
    <email>ajonkers@neochord.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Georg Nickenig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CVC Frankfurt</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Horst Sievert, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Mainz</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Andres Beiras Fernandez, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hippokration Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vasileios Lozos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Triemli Hospital</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Omer Dzemali, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Greece</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2019</study_first_posted>
  <last_update_submitted>July 9, 2020</last_update_submitted>
  <last_update_submitted_qc>July 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NeoChord</keyword>
  <keyword>DS1000</keyword>
  <keyword>Artificial Chordae</keyword>
  <keyword>Mitral Valve Repair</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
    <mesh_term>Mitral Valve Prolapse</mesh_term>
    <mesh_term>Prolapse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

